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Heart failure represents a primary cause of morbidity and mortality in older people and despite significant therapeutic
advances, it is still characterized by important unmet needs, thus remaining a challenging field of clinical research. The
recent PARADIGM-HF trial compared the novel compound LCZ696, a combination of the angiotensin receptor blocker
valsartan and the neprilysin inhibitor sacubitril, versus the angiotensin-converting enzyme inhibitor enalapril in 8,442
patients with symptomatic chronic systolic heart failure. LCZ696 led to a 20% reduction in the rate of death or
hospitalization for heart failure and a 16% reduction in the rate of all-cause death compared to enalapril at 3.5 years of
follow-up. Despite those impressive results, the clinical application of this novel agent that requires the substitution of a
cornerstone of current heart failure therapy, the angiotensin-converting enzyme inhibitors, should follow careful steps
as imposed by the study design, the recruited population and the outcome in specific patient subgroups. Further
insights into the effects of LCZ696 will be provided by the ongoing PARAGON-HF trial in patients with diastolic
heart failure.
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Heart failure (HF) represents a main cause of morbidity
and mortality and the first reason for hospital admission
in older people [1]. The important advances in the treat-
ment of HF accomplished over the past decades in terms
of drug and device therapy have resulted in a significant
improvement in the prognosis in patients with chronic
HF. The cornerstone of modern drug therapy in chronic
HF is the inhibition of neurohormonal activation that
plays a crucial role in the pathophysiology of HF devel-
opment and progression and, more specifically, of the
renin-angiotensin-aldosterone system and the sympa-
thetic nervous system [2]. Accordingly, all patients with
HF with reduced ejection fraction, unless having a
contraindication, should receive an angiotensin convert-
ing enzyme inhibitor (ACEi) or an angiotensin receptor* Correspondence: geros@otenet.gr
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unless otherwise stated.blocker (ARB) if non tolerant to ACEi, plus a beta-
blocker with the further addition of a mineralocorticoid
receptor antagonist (MRA, aldosterone or eplerenone) if
still symptomatic [2].
The incidence of HF keeps rising owing mainly to the
aging of the population and the effective management of
formerly lethal conditions, such as acute coronary syn-
dromes. This is followed by an increasing trend in HF hos-
pitalizations along with an enormous economic burden
that also keeps growing [3,4]. In addition, the outcome of
patients hospitalized for an acute HF episode remains quite
poor, with unacceptably high post-discharge mortality and
re-hospitalization rates [1]. Finally, although drug and de-
vice therapy has been proven beneficial for patients with
systolic HF, currently termed HF with reduced ejection
fraction (HFrEF), the same is not true for those with dia-
stolic HF or HF with preserved ejection fraction (HFpEF),
who roughly represent half of the total HF population and
in whom no evidence-based therapy is yet defined [2].ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Specific heart failure patient subgroups
representing a challenge for the implementation of
LCZ696 in clinical practice




Drug therapy-related characteristics ACEi-naïve patients
Intolerance to ACEi or ARB
Low ACEi dose
High ACEi dose
Patients on ARBs therapy
ACEi, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor
blockers; NYHA, New York Heart Association.
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and financial problem with several unmet needs. In this
context, HF remains a challenging field for the search for
novel therapeutic agents that would further improve pa-
tients’ outcomes.
A PARADIGM shift in heart failure therapy
The recently published ‘Prospective comparison of Angio-
tensin Receptor neprilysin inhibitors with Angiotensin
converting enzyme inhibitors to Determine Impact on
Global Mortality and morbidity in Heart Failure’ (PARA-
DIGM-HF, NCT01035255) trial applied an innovative ap-
proach to the introduction of new HF therapies. Instead
of adding the new agent on top of standard care, an ap-
proach followed by the majority of previous HF clinical
trials [2,5], PARADIGM-HF proposed the substitution of
one of the cornerstones of modern HF therapy, the ACEi
[6]. In addition, PARADIGM-HF focused on the inhibition
of the endopeptidase pathway, an import component of
the renin-angiotensin-aldosterone system not addressed
by the current HF therapies.
The new compound with the code name LCZ696 (400
mg daily), a combination of the ARB valsartan and the
neprilysin inhibitor sacubitril, was compared with the
ACEi enalapril (20 mg daily) in 8,442 patients with
symptomatic chronic HFrEF and increased levels of
natriuretic peptides [5]. At 3.5 years of follow-up,
LCZ696 had led to a 20% reduction in the incidence rate
of death or HF hospitalization and a 16% reduction in
the incidence rate of all-cause death compared to enala-
pril, results that were highly statistically significant. Re-
garding safety, LCZ696 was followed by lower rates of
hyperkalemia, renal dysfunction and cough but higher
rates of hypotension. According to a secondary analysis,
LCZ696 prevented the clinical deterioration or progres-
sion of surviving patients in terms of required treatment
intensification of therapy, hospital visits or admissions
and use of advanced management modalities (inotropes,
assist devices, transplantation) more effectively than did
enalapril [7]. Thus, the question that inevitably arises is
whether keeping HF patients on ACEi is still ethical
given those remarkable results.
The challenge of clinical application
If one takes a better look at the design of the PARADIGM-
HF trial, it seems that the clinical application of LCZ696
needs to follow careful steps. First, the study was preceded
by a single-blinded run-in phase, during which about 10%
of patients dropped out mainly due to adverse events or
abnormal laboratory results [5]. Although a run-in phase
enhances a trial’s internal validity by limiting treatment
discontinuation, on the other hand it limits the inference
of the results to the general HF population, thus affecting
the external validity. In addition, two short washoutperiods of 36 hours were applied between enalapril and
LCZ696 run-in periods and at the end of the run-in phase
to avoid overlapping of ACEi and LCZ696 that would in-
crease the risk of angioedema, a fact that renders inference
of the trial even more complicated.
According to the trial’s subgroup analyses, LCZ696
was ‘less’ beneficial in ACEi-naïve patients, while
LCZ696 led to a higher incidence of symptomatic
hypotension compared to enalapril, which, however, did
not result in a higher treatment discontinuation [5,6,8].
Those concerns are particularly important in patients
hospitalized for acute HF, in whom the use of oral medi-
cation including angiotensin aldosterone system inhibi-
tors is not sufficiently guided by available evidence [9].
Furthermore, patients who are on enalapril or equiva-
lent ACEi doses higher than those studied in the trial or
those treated with angiotensin receptor blockers may
also represent a challenge as they have not been included
in PARADIGM-HF. Finally, the cost-effectiveness of this
new strategy remains to be assessed. The HF patient sub-
groups that may pose a challenge for the clinical applica-
tion of LCZ696 according to the aforementioned issues
are outlined in Table 1.Conclusions
The results reported by the PARADIGM-HF trial inves-
tigators are indeed impressive and introduce a paradigm
shift in the treatment of chronic HFrEF. However, the
clinical application of the novel agent LCZ696 will def-
initely require a new paradigm for many HF patients.
Further to PARADIGM-HF, the ongoing PARAGON-
HF trial addresses the effects of LCZ696 on patients
with HFpEF, a condition characterized by a total lack of
evidence-based therapies, as stressed earlier, thus lead-
ing to high expectations for another major paradigm
shift in HF.
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